[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351544-105":59,"doc-detail-351544-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","egfr-targeted-extracellular-vesicles-potentiate-doxorubicin-induced-apoptosis-and-tumor-suppression-in-colorectal-cancer","EGFR-Targeted Extracellular Vesicles Potentiate Doxorubicin-Induced Apoptosis and Tumor Suppression in Colorectal Cancer","","Colorectal cancer (CRC) is driven by epidermal growth factor receptor (EGFR) overexpression and remains difficult to treat with conventional chemotherapy due to poor prognosis and limited response. This study engineered EGFR-targeted extracellular vesicles (EGFR-tEVs) displaying the GE11 peptide to improve doxorubicin (Dox) delivery specificity. EGFR-tEVDox enhanced uptake in EGFR-overexpressing HCT-116 cells and activated p53-Bax-cleaved PARP1 apoptosis. In normal fibroblasts, Dox induced p53 without significant Bax activation, indicating reduced proapoptotic signaling. In xenograft mice, EGFR-tEVs plus Dox decreased tumor volume by 33.1% and lowered Ki-67 by 82.8%, supporting improved antitumor efficacy with favorable safety.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/egfr-targeted-extracellular-vesicles-potentiate-doxorubicin-induced-apoptosis-and-tumor-suppression-in-colorectal-cancer/351544/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/egfr-targeted-extracellular-vesicles-potentiate-doxorubicin-induced-apoptosis-and-tumor-suppression-in-colorectal-cancer/351544.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How were EGFR-targeted extracellular vesicles (EGFR-tEVs) designed for doxorubicin delivery?","Question",{"text":113,"@type":114},"Donor cells were transiently engineered to display the GE11 peptide, producing EGFR-tEVs intended to enhance the precision of Dox delivery to malignant tissues.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What cellular effects did EGFR-tEVDox produce in EGFR-overexpressing cancer cells?",{"text":118,"@type":114},"EGFR-tEVDox increased cellular uptake in EGFR-overexpressing HCT-116 cells and activated the p53-Bax-cleaved PARP1 apoptotic pathway.",{"name":120,"@type":111,"acceptedAnswer":121},"How did Dox perform differently in normal colon fibroblasts versus cancer cells?",{"text":122,"@type":114},"In normal colon fibroblasts (CCD18-Co), Dox induced p53 but did not trigger significant Bax activation or PARP1 cleavage, indicating a preference for survival-related signaling in non-malignant cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351544,1790330668,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Article  \nEGFR-Targeted Extracellular Vesicles Potentiate Doxorubicin-Induced Apoptosis and Tumor Suppression in Colorectal Cancer  \nChan Mi Lee 1,2, Ji Won Choi 1, Do Sang Lee 1,2, Joo Won Moon 1, Jin Beom Cho 1,3 and Jung Hoon Bae 1,2, *  \nAcademic Editor: Rodolfo Ippoliti  \nReceived: 27 March 2026  \nRevised: 14 April 2026  \nAccepted: 17 April 2026  \nPublished: 21 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Central Institute of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; [cksal7873@cmcnu.or.kr](cksal7873@cmcnu.or.kr) (C.M.L.); [qrt97@cmcnu.or.kr](qrt97@cmcnu.or.kr) (J.W.C.); [dosangs@catholic.ac.kr](dosangs@catholic.ac.kr) (D.S.L.); [mey8010@cmcnu.or.kr](mey8010@cmcnu.or.kr) (J.W.M.); [jinbum21@catholic.ac.kr](jinbum21@catholic.ac.kr) (J.B.C.)  \n2 Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea  \n3 Division of Colorectal and Anorectal Surgery, Department of Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu 11765, Republic of Korea  \n* Correspondence: [21000592@cmcnu.or.kr](21000592@cmcnu.or.kr)  \nAbstract  \nColorectal cancer (CRC), characterized by epidermal growth factor receptor (EGFR) overexpression, is often associated with poor prognosis and limited therapeutic response to conventional chemotherapy. In this study, we developed EGFR-targeted extracellular vesicles (EGFR-tEVs) by transiently engineering donor cells to display the GE11 peptide, aiming to enhance the precision of doxorubicin (Dox) delivery. The physicochemical properties of EGFR-tEVs were characterized using TEM, NTA, and Western blot. In vitro, EGFR-tEVDox exhibited increased cellular uptake in EGFR-overexpressing HCT-116 cells, leading to the activation of the p53-Bax-cleaved PARP1 apoptotic pathway. Notably, while Dox treatment induced p53 in normal colon fibroblasts (CCD18-Co), it did not trigger significant Bax activation or PARP1 cleavage, suggesting a preference for survival-related signaling in non-malignant cells. In a xenograft mouse model, EGFR-tEVs + Dox administration resulted in a 33.1% reduction in tumor volume and an 82.8% decrease in Ki-67 expression compared to the control group. These results indicate that transient receptor-mediated targeting enhances functional drug delivery to malignant tissues while minimizing proapoptotic induction in normal cells. Our findings suggest that EGFR-tEVs + Dox represents a balanced therapeutic strategy that improves antitumor efficacy with a favorable safety profile for EGFR-positive colorectal cancer.  \nKeywords: colorectal cancer (CRC); extracellular vesicles (EVs); GE11; EGFR Target EV; p53-mediated apoptosis  \n1. Introduction  \nColorectal cancer (CRC) remains the third most frequently diagnosed cancer globally and the second leading cause of cancer-related mortality, accounting for approximately 1.9 million new cases and over 900,000 deaths annually [1–3] . Despite advances in screening, the global burden of CRC is projected to increase substantially by 2050 due to rising incidence in younger populations [4,5] . Currently, surgical resection and systemic chemotherapy are the primary treatment modalities; however, the prognosis for patients with advanced metastatic CRC (mCRC) remains dismal, with a 5-year survival rate still hovering below 15%[5,6] . The limited efficacy of conventional surgery is often attributed to  \nlate-stage diagnosis and high recurrence rates, while systemic chemotherapy is frequently hampered by dose-limiting toxicities and the lack of tumor specificity, which induces severe adverse effects in normal tissues [7] . To address these limitations, targeted therapies have emerged as a promis","cbCaio4uhIQwUhGL","https://ap.wps.com/l/cbCaio4uhIQwUhGL","pdf",6472093,18,"English","# Abstract\n# 1. Introduction\n## Global burden and current treatment limitations\n## Rationale for extracellular vesicles as drug delivery vehicles\n## EGFR targeting in colorectal cancer and therapy challenges","[{\"question\":\"How were EGFR-targeted extracellular vesicles (EGFR-tEVs) designed for doxorubicin delivery?\",\"answer\":\"Donor cells were transiently engineered to display the GE11 peptide, producing EGFR-tEVs intended to enhance the precision of Dox delivery to malignant tissues.\"},{\"question\":\"What cellular effects did EGFR-tEVDox produce in EGFR-overexpressing cancer cells?\",\"answer\":\"EGFR-tEVDox increased cellular uptake in EGFR-overexpressing HCT-116 cells and activated the p53-Bax-cleaved PARP1 apoptotic pathway.\"},{\"question\":\"How did Dox perform differently in normal colon fibroblasts versus cancer cells?\",\"answer\":\"In normal colon fibroblasts (CCD18-Co), Dox induced p53 but did not trigger significant Bax activation or PARP1 cleavage, indicating a preference for survival-related signaling in non-malignant cells.\"}]","EGFR-Targeted Extracellular Vesicles Potentiate Doxorubicin-Induced Apoptosis and Tumor Suppression in Colorectal Cancer | PDF",1790094649,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5cbfab4d37656d7069f1de8f27dff0c.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3af43ca40370266f871d56f284787b7e.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f626c67d526ba6822869619ba9ecf174.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38b6296edbf371fb6db335ba284ff17d.webp",980,1385]